PRNewsWire
13 Oct 2025, 18:34 UTC · 49w ago
Verdict
Headline takes no side. We score UNCY −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) rejecting Unicycive's New Drug Application for oxylanthanum carbonate (OLC) due to cGMP compliance deficiencies at a third-party subcontractor.
More negative than 99% of claims this week
A class action lawsuit has been filed against Unicycive and its officers alleging materially false and misleading statements regarding the company's manufacturing compliance and regulatory prospects.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
The FDA identified deficiencies in current good manufacturing practice (cGMP) compliance at a third-party vendor, which precluded label discussions with the company.
More negative than 91% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following an FDA Complete Response Letter and significant stock price drops due to manufacturing compliance failures.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
+8.3%
Price is moving against the score
$4.81 vs $4.44 close before publication (Oct 10) · not market-adjusted
UNCY chart →
